Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Alleles Anticonvulsants / administration & dosage Cytochrome P-450 CYP2C9 / genetics Genetic Variation / genetics Genotype HLA-B Antigens / genetics Humans Pharmacogenetics / methods Phenytoin / administration & dosage Stevens-Johnson Syndrome / drug therapy

Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
02 2021
Historique:
received: 24 04 2020
accepted: 25 06 2020
pubmed: 12 8 2020
medline: 22 5 2021
entrez: 12 8 2020
Statut: ppublish

Résumé

Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).

Identifiants

DOI: 10.1002/cpt.2008 PMID: 32779747 PMC: PMC7831382
pubmed: 32779747
doi: 10.1002/cpt.2008
pmc: PMC7831382
mid: NIHMS1656848
doi:

Substances chimiques

Anticonvulsants 0
HLA-B Antigens 0
Phenytoin 6158TKW0C5
CYP2C9 protein, human EC 1.14.13.-
Cytochrome P-450 CYP2C9 EC 1.14.13.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

302-309

Subventions

Organisme : NIGMS NIH HHS
ID : R24 GM115264
Pays : United States
Organisme : NIGMS NIH HHS
ID : P01 GM032165
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : NIGMS NIH HHS
ID : U01 GM092676
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM123930
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM115305
Pays : United States
Organisme : NIAID NIH HHS
ID : R34 AI136815
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105198
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM061374
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010863
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL143137
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI139021
Pays : United States
Organisme : NIGMS NIH HHS
ID : U01 GM092666
Pays : United States

Informations de copyright

© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 2010 Jul;88(1):60-8
pubmed: 20375998
Pharmacogenetics. 2002 Apr;12(3):251-63
pubmed: 11927841
Clin Pharmacol Ther. 2018 Mar;103(3):399-401
pubmed: 29134625
Front Pharmacol. 2019 Mar 26;10:149
pubmed: 30971914
PLoS One. 2015 Mar 16;10(3):e0120403
pubmed: 25775139
Clin Pharmacol Ther. 2012 Apr;91(4):734-8
pubmed: 22378157
Pharmacogenet Genomics. 2012 Jun;22(6):466-70
pubmed: 22569204
Expert Opin Drug Metab Toxicol. 2015;11(12):1893-905
pubmed: 26595139
N Engl J Med. 1995 Dec 14;333(24):1600-7
pubmed: 7477195
Pharmacogenet Genomics. 2008 Feb;18(2):99-107
pubmed: 18192896
Pharmacogenomics. 2012 Sep;13(12):1339-49
pubmed: 22966884
Br J Clin Pharmacol. 2019 Oct;85(10):2360-2368
pubmed: 31269540
Pharm Res. 2009 Apr;26(4):822-35
pubmed: 19082874
Neurology. 1997 Aug;49(2):542-6
pubmed: 9270593
Clin Pharmacol Ther. 2021 Feb;109(2):302-309
pubmed: 32779747
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:463-486
pubmed: 30134124
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:37-44
pubmed: 14616412
Clin Pharmacol Ther. 2014 Nov;96(5):542-8
pubmed: 25099164
Pharmacogenetics. 2001 Jun;11(4):287-91
pubmed: 11434505
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490672
Clin Pharmacol Ther. 2012 Dec;92(6):757-65
pubmed: 23132554
Clin Pharmacol Ther. 2018 Apr;103(4):574-581
pubmed: 29392710
Ther Drug Monit. 2004 Oct;26(5):534-40
pubmed: 15385837
Clin Pharmacol Ther. 2013 Feb;93(2):153-8
pubmed: 23232549
Clin Neuropharmacol. 2016 Sep-Oct;39(5):232-40
pubmed: 27428884
Eur J Clin Pharmacol. 2009 Apr;65(4):365-75
pubmed: 19031075
JAMA. 2014 Aug 6;312(5):525-34
pubmed: 25096692
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
Neurology. 1979 Feb;29(2):175-8
pubmed: 571061
Pharmacogenet Genomics. 2016 May;26(5):225-34
pubmed: 26928377
Seizure. 2013 Apr;22(3):194-7
pubmed: 23298603
Seizure. 2019 Mar;66:99-103
pubmed: 30826555
Eur J Clin Pharmacol. 2017 Jul;73(7):855-865
pubmed: 28391407
Aust N Z J Med. 1975 Oct;5(5):462-6
pubmed: 1061551
Ann Neurol. 2009 Apr;65(4):448-56
pubmed: 19296463

Auteurs

Jason H Karnes (JH)

Department of Pharmacy Practice & Science, University of Arizona College of Pharmacy, Tucson, Arizona, USA.
Sarver Heart Center, University of Arizona College of Medicine, Tucson, Arizona, USA.

Allan E Rettie (AE)

Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle, Washington, USA.

Andrew A Somogyi (AA)

Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.

Rachel Huddart (R)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

Alison E Fohner (AE)

Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Institute of Public Health Genetics, University of Washington, Seattle, Washington, USA.

Christine M Formea (CM)

Department of Pharmacy and Intermountain Precision Genomics, Intermountain Healthcare, Salt Lake City, Utah, USA.

Ming Ta Michael Lee (M)

Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.

Adrian Llerena (A)

INUBE Extremadura University Biosanitary Research Institute and Medical School, Badajoz, Spain.

Michelle Whirl-Carrillo (M)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

Teri E Klein (TE)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
Department of Medicine, Stanford University, Stanford, California, USA.

Elizabeth J Phillips (EJ)

Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Scott Mintzer (S)

Department of Neurology, Thomas Jefferson University Hospital Methodist Hospital Division of Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Andrea Gaedigk (A)

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Kelly E Caudle (KE)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

John T Callaghan (JT)

Department of Veteran Affairs and Departments of Medicine and Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Anticonvulsivants › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-2 de cytochromes P450 › Limonène hydroxylases › Cytochrome P-450 CYP2C9 › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Antigènes HLA-B › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Professions de santé › Pharmacologie › Pharmacogénétique › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Imidazolidines › Hydantoïnes › Phénytoïne › Clinical Pharmacogenetics Implementation...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Hypersensibilité médicamenteuse › Toxidermies › Syndrome de Stevens-Johnson › Clinical Pharmacogenetics Implementation...